The Scientific and Business Advisors team at Concarlo Holdings provides critical expertise in both the scientific and business aspects of precision medicine in oncology. This multidisciplinary group collaborates to drive research and development initiatives, ensuring innovative approaches to targeting the p27Kip1 pathway while also strategizing for market entry, partnership opportunities, and funding to support the company's growth and mission in cancer treatment.
View all